Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
Gilligan T, Lin DW, Aggarwal R, Chism D, Cost N, Derweesh IH, Emamekhoo H, Feldman DR, Geynisman DM, Hancock SL, LaGrange C, Levine EG, Longo T, Lowrance W, McGregor B, Monk P, Picus J, Pierorazio P, Rais-Bahrami S, Saylor P, Sircar K, Smith DC, Tzou K, Vaena D, Vaughn D, Yamoah K, Yamzon J, Johnson-Chilla A, Keller J, Pluchino LA. Gilligan T, et al. Among authors: saylor p. J Natl Compr Canc Netw. 2019 Dec;17(12):1529-1554. doi: 10.6004/jnccn.2019.0058. J Natl Compr Canc Netw. 2019. PMID: 31805523
[No title available]
[No authors listed] [No authors listed] PMID: 38579754
Should the denosumab metastasis prevention trial change practice for men with nonmetastatic prostate cancer?
Saylor PJ, Michaelson MD. Saylor PJ, et al. Oncologist. 2012;17(2):288-90. doi: 10.1634/theoncologist.2011-0433. Epub 2012 Jan 20. Oncologist. 2012. PMID: 22267850 Free PMC article.
The trial was positive because denosumab led to a 4.2-month significantly longer bone-metastasis-free survival time relative to placebo (median, 29.5 months versus 25.2 months; hazard ratio [HR], 0.85; 95% confidence interval [CI], 0.73-0.98; p = .028) [1]. The time to fir …
The trial was positive because denosumab led to a 4.2-month significantly longer bone-metastasis-free survival time relative to placebo (med …
Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.
Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SJ, Thamake S, Park EK, Perini RF, Linehan WM, Srinivasan R; MK-6482-004 Investigators. Jonasch E, et al. N Engl J Med. 2021 Nov 25;385(22):2036-2046. doi: 10.1056/NEJMoa2103425. N Engl J Med. 2021. PMID: 34818478 Free PMC article. Clinical Trial.
Bone health and prostate cancer.
Saylor PJ, Smith MR. Saylor PJ, et al. Prostate Cancer Prostatic Dis. 2010 Mar;13(1):20-7. doi: 10.1038/pcan.2009.50. Epub 2009 Nov 10. Prostate Cancer Prostatic Dis. 2010. PMID: 19901958 Free PMC article. Review.
72 results